Active Ingredient History

  • Now
Levosimendan (INN) is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax. Overall the drug has a two fold mechanism of action. It leads to greater ionotrophy by increasing the calcium sensitivity as it binds to Troponin and this results in a greater positive iontrophic force. Secondly, the drug is able to open ATP sensitive potassium channels in vascular smooth muscle cells, and the vascular dilatory effects of the drug lead to a decreased pre-load and afterload, putting less work on the heart. This drug is in the process of review by the FDA but has not been approved yet.   Wikipedia

  • SMILES: C[C@@H]1CC(=O)NN=C1c2ccc(NN=C(C#N)C#N)cc2
  • Mol. Mass: 280.29
  • ALogP: 1.36
  • ChEMBL Molecule:
More Chemistry
((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile | dextrosimendan | levosimedan | levosimendan | levosimendanum | odm-109 | (-)-or-1259 | or 1259 | or-1259 | or-1855 | (r)-simendan | simadax | simdax | simendan


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue